Share
* In the USA, CytoSorb is an investigational device and not authorized / cleared / approved by the US FDA for commercialization.
CytoSorbents & Hemoadsorption

When it comes to critical health challenges, rely on our experience and proven technology.

We recognize that healthcare professionals depend on high-performance technologies to support patients in complex and critical situations.

A healthy balance is vital for normal body function

Critical substances in the blood are normally tightly controlled; imbalances can result in acute harmful consequences.

 

That is why we have developed a proprietary blood purification technology to support you in managing your patients and their medical needs during critical care.

CytoSorbents’ adsorption technology

Broadening the possibilities of blood purification.

 

Offers physicians a hemoadsorption solution engineered to adsorb protein-bound and water-insoluble molecules that are typically less accessible to diffusion-based techniques such as dialysis.

 

As a result, it supports clinicians in managing complex situations by helping to stabilize physiological parameters and providing valuable time for therapeutic decisions.

  • A healthy balance is vital for normal body function

    Critical substances in the blood are normally tightly controlled; imbalances can result in acute harmful consequences.

     

    That is why we have developed a proprietary blood purification technology to support you in managing your patients and their medical needs during critical care.

  • CytoSorbents’ adsorption technology

    Broadening the possibilities of blood purification.

     

    Offers physicians a hemoadsorption solution engineered to adsorb protein-bound and water-insoluble molecules that are typically less accessible to diffusion-based techniques such as dialysis.

     

    As a result, it supports clinicians in managing complex situations by helping to stabilize physiological parameters and providing valuable time for therapeutic decisions.

By your side in critical moments

Our commitment is to provide advanced solutions designed to support healthcare professionals in delivering high-quality patient care.

Our expertise in hemoadsorption

We go beyond developing advanced medical devices — we continuously generate and share substanciated scientific and clinical knowledge to support physicians and clinical partners in the effective use of our technologies.

Global team of 150+ experts
Pioneering in Research & Development
Extensively investigated hemoadsorption technology across multiple applications such as Cytokine, Bilirubin, Myoglobin and / or Ticagrelor/Rivaroxaban removal
Customized training & support materials
24/7 support & expertise on demand
User-Driven Product Solutions
  • Global team of 150+ experts
  • Pioneering in Research & Development
  • Extensively investigated hemoadsorption technology across multiple applications such as Cytokine, Bilirubin, Myoglobin and / or Ticagrelor/Rivaroxaban removal
  • Customized training & support materials
  • 24/7 support & expertise on demand
  • User-Driven Product Solutions

Additional Information

  • Mitzner et al. J Clin Med. 2023;12(23):7199
  • Schmoeckel et al., J Throm & Thrombolysis 2024; epub
  • Doukas et al., J Clin Med 2023; 12:546
  • Haidari et al., ICV&TS 2023; 36(1):ivad010
  • Nemeth et al., ESC Heart Failure 2024; 11(2):772-782
  • Grafe et al., Ren Fail 2023; 45(2):2259231
  • Haselwanter et al., Sci Rep 2024; 14(1):11309
  • Jansen et al., Critical Care 2023; 27(1):117
  • Akil et al., J Clin Med 2022; 11(20):5990

 
CytoSorb 300 IFU 03/2023 – Indications:
CytoSorb is indicated for use in conditions where elevated levels of cytokines and/or bilirubin and/or myoglobin exist. CytoSorb is indicated for use intraoperatively during cardio-pulmonary bypass surgery for the removal of P2Y12-Inhibitor Ticagrelor and/or Factor Xa-Inhibitor Rivaroxaban. Results from current studies suggest that CytoSorb may be administered for up to 7 consecutive days. Maximum Treatment Time per Device: 24 Hour.

For comprehensive professional support in patient care.

Clinical experience and published studies have described associations between CytoSorb® Therapy and improvements in patient-management parameters. Healthcare professionals worldwide continue to explore its potential role in supporting treatment strategies across diverse critical-care settings.

Find out about our Innovation
CytoSorbents

Voices around the world

world map
Critical Care
Prof. Steffen Mitzner
Rostock, Germany

What strikes you first is that you can stabilize patients in septic shock.

Cardiovascular
Prof. Dr. Yeong-Hoon Choi
Bad Nauheim, Germany

We were able to decrease the need for circulatory supporting medications accordingly, very, very quickly to a tolerable level.

Cardiovascular
Dr. Helmut Mair
Munich, Germany

We had no bleeding problems whatsoever. The adsorber was in use throughout the operation. It worked really well. We believe in this product.